IVD Leader Makes Two Strategic Moves in Three Days to Accelerate Life Science Platform Building
Sansure Biotech
Provider of Total Solutions for In Vitro Diagnostics
PHIL RIVERS
Medical Information Technology Service Provider
This is already Sansure Biotech's second major investment in just three days.. On March 12, the company just announced an investment of 90 million yuan in AI medical enterprises.PHIL RIVERSThe continuous strategic moves reflect Sansure Biotech's determination to accelerate its transformation into a "diversified platform enterprise in the life science and technology field."
Vasmed was founded in 2016, and its core advantage lies in itsProprietary infrared fluorescence enhancement technology, a key underlying platform technologyWith its strong anti-interference capability and excellent penetration in the near-infrared light spectrum, it can significantly enhance detection sensitivity and accuracy. This makes it a key technological platform for achieving ultra-sensitive detection and multi-index joint testing.
Currently, itsA variety ofImmune Fluorescence POCT Diagnostic Reagent Kits and Supporting Instruments Cover Chronic Disease Management, Infectious Diseases, Cancer, and Reproductive Health. To date, they have obtained over 20 NMPA registration certificates in China and more than 60 EU CE certifications, with products applicable to clinical settings within hospitals and primary healthcare scenarios.
The Strategic Value of Underlying Technology
From the financial data, Hwasu is still in the early investment stage.
As of December 31, 2025, the company's total assets amounted to 8.539 million yuan, total liabilities to 20.6382 million yuan, and net assets stood at -12.0993 million yuan; in the fiscal year 2025, it generated operating revenue of 3.2015 million yuan with a net loss of 6.914 million yuan.However, if we only look at the data, it is obviously too superficial.
Sansure Biotech Clearly Explained the Synergistic Logic Behind This Acquisition in the Announcement:Technical LevelInfrared fluorescence technology, as a foundational platform technology, can complement Sansure's existing molecular diagnostics and immunoassay products, enhancing the overall product performance.Business Level, WASUV's equipment features miniaturization and low cost. Its testing reagents are mostly related to chronic disease management, which aligns well with the company’s strategic focus on consumer healthcare and primary healthcare. Moreover, it can effectively complement the company’s existing line of infectious disease detection products.
Sansure Biotech's performance trajectory in recent years shows that the operating revenues for 2022, 2023, and 2024 were 6.45 billion yuan, 1.007 billion yuan, and 1.458 billion yuan respectively, with net profits attributable to parent company shareholders being 1.937 billion yuan, 364 million yuan, and 276 million yuan respectively. The 2025 annual earnings快报 reveals that the company achieved an operating revenue of 1.648 billion yuan, representing a year-on-year increase of 13.04%; the net profit attributable to parent company shareholders was 198 million yuan, reflecting a year-on-year decrease of 28.10%. It is evident that while revenue has stabilized, profits continue to decline, primarily due to the VAT rate increasing from 3% to 13%, compounded by the centralized procurement policy.
This may prompt Sansure Biotech to accelerate and firmly advance its strategic transformation.
In terms of R&D, the investment in 2025 will be approximately 310 million yuan, accounting for nearly 20% of operating revenue; while another path is external expansion through mergers and acquisitions, which is also a developmental history shared by many international giants.
Five Years, Seven Key Transactions
Unfolding Sansure Biotech's "M&A Long Scroll," a platform ecosystem woven by multiple key transactions comes clearly into view. Since 2021, through a series of M&A investments, it has gradually built up a life science technology platform covering the entire chain of "prevention-diagnosis-treatment-management," with great ambition.
2021: Embarking on the Journey of Mergers and Acquisitions,In 2022, Sansure Biotech acquired 14.77% of GenoCare Biotech, a gene sequencing company, for 255.2 million yuan, becoming its second-largest shareholder and officially entering the gene sequencer market. In 2021, the company invested in QuantuMDx, a UK-based molecular POCT company, to enhance its POCT testing equipment R&D capabilities.
In May 2022, acquired 21.69% of First Light's equity.The transaction amount was $2.22 million. The latter is a company focused on the development of rapid detection products for antibiotic drug sensitivity.
Ramped Up Chemiluminescence in 2023,In May, Sansure Biotech invested 1.71 billion yuan in Shenzhen Ansaic through equity transfer and capital increase in the form of a joint venture, entering the electrochemiluminescence field.
In 2024, the rapid testing layout will be improved.In May, the acquisition of 100% equity in Hunan Sunvictor Rapid Microbial Biotechnology Co., Ltd. was completed for a transaction amount of 123 million yuan, strengthening the rapid antimicrobial susceptibility testing field.
A Wave of Enthusiasm for "Integrated Diagnosis and Treatment" in 2025In January, Sansure Biotech acquired Zhongshan Weiming Haiji Biotechnology for 807.5 million yuan, entering the growth hormone market, marking the largest acquisition and a significant move from "diagnostics" to "therapeutics." In February, it invested 75.6 million yuan in Changsha Red Bank Base, holding 54% equity after the share transfer and capital increase transactions, entering the hematology field.
By 2026, its globalization and AI deployment have deepened further,In January, the company acquired inno-train Diagnostik, a leading German enterprise in global HLA diagnostics and molecular blood diagnostics, significantly enhancing its competitiveness in high-barrier niche fields in China such as transfusion safety and organ transplantation. In March, it successively invested in PHIL RIVERS (AI healthcare) and acquired Huaswuwei (infrared fluorescence POCT), further improving the industrial chain layout.
From a single-dimensional platform to an IVD platform model, from testing to integrated diagnosis and treatment, and from a domestic star to a global prototype, Sansure Biotech is showing an increasingly strong momentum.
Conclusion
Sansure Biotech's transformation path is clear: from a leader in molecular diagnostics to an IVD platform enterprise, and then to an integrated healthcare enterprise encompassing both diagnosis and treatment.
By acquiring enterprises with core technologies but limited markets, a platform ecosystem featuring technology complementarity and market synergy is built.Infrared fluorescence technology, gene sequencing, growth hormone product lines, HLA diagnostic technology—these seemingly scattered technologies are being integrated into a healthy management system.
Its mergers and acquisitions expansion is not an isolated case. Against the backdrop of the current complex and volatile global economic environment, as well as the procurement pressures and transformation challenges faced by China's medical industry, there are quite a few companies in similar situations.
Because companies with a single product line face greater risks, while platform-based ones can diversify risks. Sansure Biotech did not stop but continued to advance strategic mergers and acquisitions, taking the initiative to seek growth opportunities in adversity, believing that when spring arrives, they will reap bountiful rewards.
References:
1. Sansure Biotech Plans to Invest 65.438 Million Yuan with Related Parties to Establish a Company for Acquisition, Radar Finance, 2026
2. Sansure Biotech Acquires Growth Hormone Company at 2x Premium, "Not Short of Money" Sansure Biotech on Shopping Spree, Former Alibaba CEO Wei Zhe Joins, Era Weekly, 2025
3.Two consecutive acquisitions at the beginning of the year, Sansure Biotech enters the hematology analyzer market,打通基层检验“最后一公里”丨M&A Frontline, Titanium Media, 2025